Australian Clinical Labs Ltd (ASX: ACL) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Australian Clinical Labs Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $496.51 million
P/E Ratio 32.38
Dividend Yield 4.03%
Shares Outstanding 201.83 million
Earnings per share 0.077
Dividend per share 0.10
Year To Date Return -13.15%
Earnings Yield 3.09%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Australian Clinical Labs Ltd (ASX: ACL)
    Latest News

    A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
    Dividend Investing

    3 magnificent ASX dividend shares that could turn $5k into $50,000

    Growth stocks aren't the only way to a massive windfall. Here's a trio I think that could also take you…

    Read more »

    A woman gives a side eye look with her lips pursed as though she might be saying ooh at something she's hearing or learning for the first time.
    Dividend Investing

    12 ASX dividend shares with yields over 10%. Are they too good to be true?

    Is a 10% yield a good or a bad sign for an income share?

    Read more »

    Two happy scientists analysing test results in a lab
    Healthcare Shares

    Which ASX All Ords healthcare share has a 20% dividend yield?

    Why is this small-cap company's gross trailing dividend yield so high, and is it sustainable?

    Read more »

    A man points at a paper as he holds an alarm clock.
    Dividend Investing

    8 ASX All Ords shares trading ex-dividend this week

    These ASX shares will soon allocate their upcoming dividends to shareholders.

    Read more »

    A telehealth doctor at her desk.
    Healthcare Shares

    Why this ASX All Ords healthcare share is defying the market weakness and zooming higher

    Australian Clinical Labs has made a bold takeover approach for its larger rival.

    Read more »

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    Healius share price jumps 7% on takeover approach from smaller rival

    Could Healius about to be taken over by a smaller rival?

    Read more »

    Two boys with cardboard rockets strapped to their backs, indicating two ASX companies with rocketing share prices
    Share Gainers

    Catch these fast-rising 2 ASX shares before it's too late: Celeste

    This pair of stocks rocketed up in February during reporting season, but are still great value for those willing to…

    Read more »

    three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
    Small Cap Shares

    'Very attractive valuations': Experts name 3 small-cap ASX shares to buy

    If you agree that smaller companies are ready to roar again in 2023, here is a trio of stocks to…

    Read more »

    A older man and younger man rest, exhausted but happy after a good boxing session.
    Cheap Shares

    2 hammered ASX shares to buy before they rise again: Celeste

    If you're purchasing a house you'd want it for the lowest price. So why is it any different for stocks?

    Read more »

    A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
    Healthcare Shares

    Are healthy returns on the horizon for ASX 200 healthcare shares in 2023?

    Will the healthcare sector make a full recovery from COVID this year?

    Read more »

    Two children hold on tightly to books hugged against their chests, as if they were holding on to ASX shares for the long term.
    Investing Strategies

    16% dividend yield: Fund names 2 slammed ASX shares to buy for the long run

    If you're in a skittish market, then the trick is not to become skittish yourself. Here's a pair of quality…

    Read more »

    A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
    Share Fallers

    Why ANZ, Australian Clinical Labs, Core Lithium, and Kogan are sinking today

    These ASX shares are sinking on Thursday...

    Read more »

    Frequently Asked Questions

    Yes, Australian Clinical Labs has historically paid two fully franked shareholder dividends a year.

    Australian Clinical Labs generally pays its shareholder dividends in April and September.

    Australian Clinical Labs Ltd listed on the ASX on 14 May 2021.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    28 Mar 2024 $0.0300 100.00% Interim 26 Apr 2024
    27 Mar 2023 $0.0700 100.00% Interim 26 Apr 2023
    23 Aug 2022 $0.4100 100.00% Final 15 Sep 2022
    25 Mar 2022 $0.1200 100.00% Interim 21 Apr 2022

    ACL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Australian Clinical Labs Ltd

    Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.

    Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing. 

    In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.

    ACL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 Jul 2024 $2.46 $-0.02 -0.81% 124,820 $2.45 $2.49 $2.44
    19 Jul 2024 $2.48 $0.06 2.48% 205,499 $2.41 $2.49 $2.41
    18 Jul 2024 $2.42 $0.05 2.11% 22,515,169 $2.37 $2.42 $2.33
    17 Jul 2024 $2.37 $0.00 0.00% 278,788 $2.36 $2.42 $2.34
    16 Jul 2024 $2.37 $-0.08 -3.27% 2,027,028 $2.41 $2.45 $2.34
    15 Jul 2024 $2.45 $-0.01 -0.41% 448,361 $2.50 $2.50 $2.39
    12 Jul 2024 $2.46 $0.05 2.07% 249,659 $2.41 $2.47 $2.41
    11 Jul 2024 $2.41 $0.01 0.42% 460,464 $2.43 $2.45 $2.40
    10 Jul 2024 $2.40 $0.00 0.00% 1,575,460 $2.38 $2.40 $2.32
    09 Jul 2024 $2.40 $-0.10 -4.00% 780,503 $2.50 $2.53 $2.37
    08 Jul 2024 $2.50 $-0.03 -1.19% 497,771 $2.53 $2.54 $2.50
    05 Jul 2024 $2.53 $0.01 0.40% 365,108 $2.55 $2.55 $2.48
    04 Jul 2024 $2.52 $0.04 1.61% 164,914 $2.47 $2.52 $2.47
    03 Jul 2024 $2.48 $-0.02 -0.80% 408,429 $2.50 $2.51 $2.46
    02 Jul 2024 $2.50 $-0.01 -0.40% 582,408 $2.50 $2.54 $2.47
    01 Jul 2024 $2.51 $0.00 0.00% 355,887 $2.50 $2.54 $2.47
    28 Jun 2024 $2.51 $0.00 0.00% 242,773 $2.56 $2.57 $2.49
    27 Jun 2024 $2.51 $-0.05 -1.95% 1,220,869 $2.54 $2.57 $2.45
    26 Jun 2024 $2.56 $-0.04 -1.54% 1,412,791 $2.62 $2.64 $2.51
    25 Jun 2024 $2.60 $-0.02 -0.76% 375,036 $2.58 $2.64 $2.55
    24 Jun 2024 $2.62 $0.00 0.00% 541,417 $2.60 $2.63 $2.59

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Feb 2024 Christine Bartlett Buy 20,000 $47,154
    On-market trade. As per announcement on 05-03-2024
    20 Dec 2023 Melinda McGrath Issued 395,490 $901,717
    Issue of securities. vwap, 880,836 Rights, As per announcement on 04-01-2024

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Thomas Alscher Non-Executive DirectorNon-Executive Chairman Dec 2020
    Mr Alscher is the Managing Partner and founder of Crescent, an Australian private equity investment firm, specialising in growth companies and certain industry sectors such as healthcare. He is Chair of Risk Committee. Prior to founding Crescent in 2000, Michael was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles. He is also member of the Risk Committee.
    Dr Leanne Rowe Non-Executive Director Apr 2021
    Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health, and community health. Leanne is currently a Non-Executive Director of Bupa ANZ Group and a Presiding Member for Medical Panels Victoria.
    Mr Andrew Mark Rendle Dutton Non-Executive Director Apr 2021
    Mr Dutton has over 30 years of management, business development and technology experience across Australia, Asia and Europe. Andrew is the current Chair of Land Registry Services and was recently an Advisor to FinancialForce APJ. He has had Chief Executive Officer and Board experience globally and within Australia. He is also member of the Risk Committee.
    Mr Nathanial Jonothan Thomson Non-Executive Director Dec 2020
    Mr Thomson is a Partner at Crescent, an Australian private equity investment firm. Nathanial has over 20 years of experience in strategy consulting, private equity, and investment banking. He has consulting experience from his prior role at McKinsey & Co.
    Ms Christine Nildra Bartlett Non-Executive Director Aug 2023
    Ms Bartlett has executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a strong commercial perspective, particularly in fostering innovation and leveraging new emerging technologies.
    Mr Mark Haberlin Non-Executive Director Apr 2021
    Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate, and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is also member of the Risk Committee.
    Ms Melinda Leigh McGrath Chief Executive OfficerExecutive Director Dec 2020
    Ms McGrath has been the Chief Executive Officer and Executive Director of ACL's predecessor corporate vehicle, Clinical Laboratories Pty Ltd since 2015. Melinda has led the organization's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance-oriented culture across the organization, via one unified integrated pathology system.
    Ms Eleanor Padman Company Secretary
    James Davison Chief Financial Officer
    Eleanor Padman Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Crescent Capital Partners V Lp. 34,579,411 17.13%
    Hsbc Custody Nominees (Australia) Limited 33,314,369 16.51%
    J P Morgan Nominees Australia Pty Limited 25,262,126 12.52%
    Citicorp Nominees Pty Limited 20,122,838 9.97%
    National Nominees Limited 13,940,616 6.91%
    Instanz Nominees Pty Ltd 9,514,668 4.71%
    Ccp Trusco 1 Pty Ltd 8,919,642 4.42%
    BNP Paribas Noms Pty Ltd 5,961,920 2.95%
    Ccp Trusco 2 Pty Ltd 3,908,488 1.93%
    Melinda Mcgrath 2,173,867 1.08%
    Hsbc Custody Nominees (Australia) Limited i 2,131,656 1.06%
    Perpetual Corporate Trust Ltd 2,084,287 1.02%
    Perpetual Corporate Trust Ltd i 1,786,533 0.89%
    ACL Employee Share Trusco Pty Ltd 1,330,743 0.66%
    Mr Nicholas Barry Debenham & Mrs Annette Cecilia Debenham 1,080,800 0.54%
    Dr Anthony James Landgren 838,211 0.42%
    Anthony Friedli 754,390 0.37%
    A.C.N. 633 176 100 Pty Ltd 749,464 0.37%
    Akat Investments Pty Limited 600,000 0.30%
    Paul Gerard Richard 574,649 0.28%